Substance / Medication

Diethylpropion

SNOMED 387303009 UMLS C0012201

Overview

Active Ingredient

diethylpropion

RxNorm CUI

3389

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Obesity

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Cholesterol

LOINC 2093-3

secondary

Hemoglobin A1c

LOINC 4549-2

secondary

Triglyceride

LOINC 2571-8

secondary

Clinical Trials

426 trials linked to this intervention

426

Total Trials

122

Recruiting

109

With Results

Recent Trials

Diabetes and Heart Disease Risk in Blacks

NCT00001853Recruiting2000 enrolled

Testosterone for HIV-Positive Men With Reduced Serum Testosterone Levels and Abdominal Fat

NCT00009555Phase 4Completed86 enrolled

Pediatric Hypothalamic Obesity

NCT00076362Phase 4Completed60 enrolled

The Safety and Effectiveness of Low and High Carbohydrate Diets

NCT00079547Phase 4Completed307 enrolled

Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity

NCT00134303Phase 4Completed65 enrolled

View all 426 trials on ClinicalTrials.gov

Research Evidence

Published studies and systematic reviews

Sort:

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects.

Cercato C, Roizenblatt V A, Leança C C et al. · Int J Obes (Lond) · 2009

PMID: 19564877RCT

The efficacy of the appetite suppressant, diethylpropion, is dependent on both when it is given (day vs. night) and under conditions of high fat dietary restriction.

Kalyanasundar B, Solorio Jessica, Perez Claudia I et al. · Appetite · 2016

PMID: 26867698Observational

Neurochemical and behavioral effects elicited by bupropion and diethylpropion in rats.

Santamaría Abel, Arias Hugo R · Behav Brain Res · 2010

PMID: 20307582Observational

Serotonin1A-receptor antagonism blocks psychostimulant properties of diethylpropion in marmosets (Callithrix penicillata).

Mello Eldon L, Maior Rafael S, Carey Robert J et al. · Eur J Pharmacol · 2005

PMID: 15777778Observational

Primary pulmonary hypertension after amfepramone (diethylpropion) with BMPR2 mutation.

Abramowicz M J, Van Haecke P, Demedts M et al. · Eur Respir J · 2003

PMID: 14516151Case Report

Clinical and oculographic response to Tenuate Dospan (diethylpropionate) in a patient with congenital nystagmus.

Hertle Richard W, Maybodi Mitra, Mellow Susan D et al. · Am J Ophthalmol · 2002

PMID: 11755862Case Report

Combination of diethylpropion with dietary intervention results in body weight and fat loss with preserved muscle mass in obese patients.

Nugraha Gaga Irawan, Amalia Fiki, Imadudda'wah Fata et al. · Medicine (Baltimore) · 2024

PMID: 39331885OtherFull text (PMC)

Diethylpropion and mazindol: An end to the discussion?

Lucchetta Rosa Camila, Riveros Bruno Salgado, Pontarolo Roberto et al. · Rev Assoc Med Bras (1992) · 2017

PMID: 28489121Other

Anorectic interaction and safety of 5-hydroxytryptophan/carbidopa plus phentermine or diethylpropion in rat.

Limón-Bernal Ernesto, Roa-Coria José E, Zúñiga-Romero Ángel et al. · Behav Pharmacol · 2021

PMID: 33660661Preclinical

Anorectic efficacy and safety of the diethylpropion-topiramate combination in rats.

Cortés-Moreno Gabriela Y, Roa-Coria José E, Zúñiga-Romero Ángel et al. · Drug Dev Res · 2018

PMID: 30188585Preclinical

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Specialists

Providers who commonly manage this intervention

Obesity Medicine (Family Medicine) Physician

Family Medicine — Obesity Medicine

NUCC 207QB0002X

Obesity Medicine (Internal Medicine) Physician

Internal Medicine — Obesity Medicine

NUCC 207RB0002X

Endocrinology, Diabetes & Metabolism Physician

Internal Medicine — Endocrinology, Diabetes & Metabolism

NUCC 207RE0101X

Find a Provider

Health Goals

Goals connected through associated conditions

Manage Weight and Body Composition Optimize Metabolic Function

Quick Facts

Type: Substance / Medication
Fully Specified Name: Amfepramone (substance)
SNOMED CT: 387303009
UMLS CUI: C0012201
RxNorm CUI: 3389

Clinical Data

This intervention maps to 9 entities in the Healos knowledge graph.

Conditions

Biomarkers

Specialists

Symptoms

426

Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.